AI and the Unbundling of Primary Care
Primary care has been the victim of pundits touting AI replacing doctors since ChatGPT was released. But something quieter and more consequential is actually happening.
Primary care isn't being replaced. It's being unbundled. And AI is becoming the hub that the PCP never had the time or infrastructure to be.
What We'll Dig Into
AI as the new front door. From symptom triage to risk stratification, how is AI displacing the PCP as the first point of contact — and what happens to the patient relationship?
The coordination thesis. If AI becomes the connective tissue across fragmented care, does primary care lose its reason for being? Or does it finally get to focus on what it does best?
Who controls the algorithm. Payers, health systems, and tech companies all want to own the AI layer. Who wins that fight — and what are the downstream consequences?
The rebundling question. Does AI-driven unbundling create so much fragmentation that someone has to put it all back together? What does rebundled, AI-native primary care actually look like?
The legal and regulatory reality. Liability, reimbursement, scope of practice — what's the framework when an AI layer is making decisions that used to belong to a physician?
Panelists:
Abe Kwon, Partner, Lowenstein Sandler
Chethan Sarabu, Director of Clinical Innovation, Health Tech Hub, Cornell Tech
Bhumika Agarwalla, Senior Director of GenAI at Blue Health Intelligence (BCBS)
Moderated by Alexander Singh, Sr. Director of Data at knownwell and Investment Partner at Pioneer Fund.
About Lowenstein Sandler:
Lowenstein Sandler’s Emerging Companies & Venture Capital (ECVC) group provides a tailored approach to the legal strategies and services essential for the successful launch, growth, and culmination of new enterprises. Our collaborative, multidisciplinary ECVC practice takes a 360° approach to innovation, investment, and business, representing both investors and startups throughout all stages of a company’s life cycle.
Each year, our ECVC group helps create hundreds of new businesses and closes thousands of transactions. Because we represent both investors and companies seeking financing, we are ideally positioned to facilitate fruitful relationships between startup, emerging, and growth companies and providers of capital. Our law firm serves as outside general counsel to many technology and life science companies, often counseling them on matters involving financings, licensing, and intellectual property.
Have questions or want to connect? Reach out to Abe Kwon (Partner, Emerging Companies & Venture Capital, Lowenstein Sandler) at [email protected].